Copegus Articles
Licensing deals: Debiopharm/Novartis; Teva/Active Biotech; Qiagen on biomarker; Merck & Co/AnaptysBio; and Novavax/ROVI accord dropped
9 February 2010
Larger proportion of hepatitis C non-responder patients in USA will get telaprevir therapy than boceprevir, study shows
20 January 2010
Stock Commentary - New York week to April 27, 2009
30 April 2009
Debiopharm hails strong results with HCV drug
28 April 2009
Vertex' telaprevir achieves unprecedented SVR
27 April 2009
Anadys shares drop 35% on mixed HCV drug data
24 April 2009
GlobeImmune's Tarmogen plus SOC shows 94% EVR
24 April 2009
PEG-INF lambda reduces HCV RNA with no liver AEs
24 April 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
FDA expands indication for S-P hep C combo
30 March 2009
Romark's nitazoxanide boosts SVR of SOC
30 March 2009
Advantages of telaprevir- and boceprevir-based regimens
23 March 2009
HGS/Novartis drug non- inferior to Pegasys
16 March 2009
Japan stock market week to Feb 23, 2009
2 March 2009
Amarillo hep C agent cleared for Ph II in Taiwan
23 February 2009
Schering-Plough finally back in profit after Organon buy; exceeds expectations, pleasing shareholders
9 February 2009
Roche agrees hep C trial design with FDA
19 January 2009
S-P's Pegintron/Rebetol approved in children
22 December 2008
Stock Commentary - New York week to Dec 1, 2008
8 December 2008
S-P claims superior pipeline to competitors; new drugs could make $7B in next 4 years
8 December 2008
Taribavirin: lower anemia rates than ribavirin
8 December 2008
"Unprecedented" 75% SVR24 for boceprevir
1 December 2008
S-P's boceprevir doubles SVR24 in Ph II study
10 November 2008
Pegasys/Copegus effective in non-responders
10 November 2008
52% of telaprevir patients achieve SVR12
10 November 2008
Expanded European indication for Roche's Pegasys/Copegus
8 November 2008
Cytheris' CYT107 enters Ph I/IIa trial
3 November 2008
EU and US regulators approve pivotal Ph III telaprevir trial
1 September 2008
S-P's boceprevir shows 74% SVR in HCV
11 August 2008
EU's pediatric drug c'tee celebrates first birthday
28 July 2008
S-P to initiate Ph III boceprevir program
2 June 2008
Roche to lift stake in Chugai to 59.9%
2 June 2008
Pharma to be creative on generics threat
5 May 2008
Promising Ph IIa data on Roche's R1626
5 May 2008
Similar SVRs for S-P and Roche HCV combos
5 May 2008
S-P's boceprevir sees 57% SVR at 28 weeks
5 May 2008
OctoPlus presents Locteron study results
28 April 2008
Schering-Plough to deliver Hep C data
28 April 2008
SciClone and Sigma-Tau report promising Ph III Zadaxin data
18 February 2008
OctoPlus begins dosing in US Locteron study
11 February 2008
Further EU approval for S-P's HCV drug combo
26 November 2007
GSK initiates Ph III hep C Promacta studies
21 November 2007
Roche drug combo helps Pegintron-resistant patients
21 November 2007
Strong HCV clearance data for R1626 regimen
21 November 2007
Pegintron plus Rebetol achieves consistent SVR
21 November 2007
Telaprevir achieves SVR in over 60% of HCV-1 patients
21 November 2007
OctoPlus to raise 25M euros to fund pipeline development
19 November 2007
Valeant slumps into 3rd-qtr $12M loss
12 November 2007
Stock Commentary - New York week to Nov 5, 2007
12 November 2007
HGS' Albuferon sees strong Ph IIb data
12 November 2007
S-P's boceprevir boosts HCV clearance rates
29 October 2007
CHMP recommends S-P's HCV drug regimen
1 October 2007
Roche initiates landmark HCV drug therapy trial
24 September 2007
Wyeth/ViroPharma discontinue Ph II study of HCV-796
20 August 2007
Strong Ph IIa data for OctoPlus' Locteron
30 July 2007
Toray seeks approval of Feron plus ribavirin
18 June 2007
Phynova initiates Ph IIa US trial of PYN17
4 June 2007
Mixed Ph IIb data for Idenix' HCV combo
23 April 2007
Strong Ph II data on Intarcia's omega-INF
23 April 2007
Polish biotech Bioton buys Biopartners
26 March 2007
Roche initiates PROGRESS trial
19 March 2007
13 new drugs added to Japan's NHI list
19 March 2007
HGS starts dosing in Ph III Albuferon trial
12 March 2007
EC clears short-course Pegasys/Copegus
12 March 2007
Copegus/Pegasys gets MHLW OK for Hep C
5 February 2007
Stock Commentary - New York week to Oct 30, 2006
6 November 2006
Valeant reports strong 48-week data for Infergen
6 November 2006
SVR for early responders on Pegasys/Copegus
6 November 2006
S-P announces its AASLD presentation program
6 November 2006
ViroPharma and Wyeth start Ph II trial of HCV antiviral
30 October 2006
Roche initiates Ph II trial of novel HCV drug
23 October 2006
Forthcoming GSK eltrombopag data
16 October 2006
UK OKs combination hepatitis C treatments
4 September 2006
UK's NICE guidance on hepatitis C treatment OKs two drugs
28 August 2006
Sho-saiko-to in Ph I as hepatitis C therapy
12 June 2006
Roche's Copegus/Pegasys "cost effective," study
29 May 2006
Valeant 1st-qtr 2006 loss deepens to $6.4M
15 May 2006
Roche's Pegasys "better at 24, not 16 weeks"
8 May 2006
Strong Ph I data for Roche's novel HCV drug
8 May 2006
S-P granted EU label change for Intron A
1 May 2006
Novelos hep C drug IND accepted by FDA
1 May 2006
Copegus 400mg OKed in Holland, MRP begun
1 May 2006
Novelos submits IND to US FDA on HCV drug
3 April 2006
Idenix lowers NM283 dosage after AE reports
3 April 2006
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
